Shaker R. Dakhil

机构：Cancer Center of Kansas · ORCID：0000-0002-6261-5882

发表论文 442 篇 · 总被引 38128 次 · h-index 82

代表论文

• Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes (2024 · Nature Genetics · 被引 83)
• Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment (2024 · Journal for ImmunoTherapy of Cancer · 被引 64)
• Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer (2025 · JAMA Network Open · 被引 25)
• Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial (2024 · Journal of Clinical Oncology · 被引 13)
• Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). (2024 · Journal of Clinical Oncology · 被引 11)
• Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer (2024 · Human Vaccines & Immunotherapeutics · 被引 7)